1. Home
  2. ZLAB vs SUPN Comparison

ZLAB vs SUPN Comparison

Compare ZLAB & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zai Lab Limited

ZLAB

Zai Lab Limited

SELL

Current Price

$22.62

Market Cap

2.6B

Sector

Health Care

ML Signal

SELL

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

SELL

Current Price

$40.39

Market Cap

2.5B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
ZLAB
SUPN
Founded
2013
2005
Country
China
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.5B
IPO Year
2017
2010

Fundamental Metrics

Financial Performance
Metric
ZLAB
SUPN
Price
$22.62
$40.39
Analyst Decision
Strong Buy
Buy
Analyst Count
12
4
Target Price
$33.14
★ $61.75
AVG Volume (30 Days)
★ 712.3K
624.7K
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 38.46
N/A
EPS
★ N/A
N/A
Revenue
★ $460,156,000.00
$392,755,000.00
Revenue This Year
N/A
$23.21
Revenue Next Year
$26.50
$54.85
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 15.33
N/A
52 Week Low
$15.96
$40.51
52 Week High
$30.00
$59.68

Technical Indicators

Market Signals
Indicator
ZLAB
SUPN
Relative Strength Index (RSI) 34.34 36.12
Support Level $16.97 $40.51
Resistance Level $27.14 $52.33
Average True Range (ATR) 1.03 1.51
MACD -0.36 -0.08
Stochastic Oscillator 9.48 4.73

Price Performance

Historical Comparison
ZLAB
SUPN

About ZLAB Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: